January 20, 2016 – The American Food and Drug Administration (FDA) just approvedOfatumumab (Arzerra) Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab, also known as HuMax-CD20, is a fully human monoclonal antibody directed against the CD20 protein which appears to inhibit early-stage B lymphocyte activation. Ofatumumab (Arzerra) was previously approved for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy was considered inappropriate and also for patients with CLL refractory to Fludarabine and Alemtuzumab (Campath).
The recommended dose and schedule for Ofatumumab (Arzerra) therapy in this indication is 300 mg by intravenous infusion on day 1 followed by 1,000 mg on day 8 and then 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years.
This new approval was based on demonstration of an improvement in progression-free survival (PFS) in a randomized, open-label trial comparing Ofatumumab (Arzerra) to observation in patients whose disease had a complete or partial response after at least two lines of prior therapy. A total of 474 patients were randomized (1:1) to Ofatumumab (Arzerra) (n=238) or observation (n=236). The median age was 64.5 years (range 33-87). Patients in the Ofatumumab (Arzerra) arm had received a median of 2 prior therapies (range 2-5). The investigator-assessed median PFS was 29.4 months (95% CI: 26.2, 34.2) and 15.2 months (95% CI: 11.8, 18.8) in the Ofatumumab (Arzerra) and observation arms, respectively [HR: 0.50 (95% CI: 0.38, 0.66), p-value < 0.0001].
Ofatumumab (Arzerra) comes with serious adverse effects for some patients. The most common adverse reactions (greater than or equal to 10%) in patients treated with Ofatumumab (Arzerra) therapy were infusion reactions, neutropenia and upper respiratory tract infection. Thirty-three percent of patients treated with Ofatumumab (Arzerra) reported serious adverse reactions. The most common serious adverse reactions were pneumonia, pyrexia and neutropenia (including febrile neutropenia). In addition, Ofatumumab (Arzerra) comes with a Boxed Warning which very prominently warns about the possibility of Hepatitis B Virus (HBV) Reactivation in patients receiving CD20-directed cytolytic antibodies, including Ofatumumab (Arzerra), resulting in some cases in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including Ofatumumab (Arzerra), as well.
About the Author
Ph.D.; Professor in Pharmacology and Toxicology.
Senior expert in theragenomic and personalized medicine and individualized drug safety.
Senior expert in pharmaco- and toxicogenetics.
Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
No comments yet
Report Content to Admin
Reason for Report:
ERROR: Please select Reason for Report.ERROR: Please fill Reason for Report.
Investigators at St. Jude Children's Research Hospital, the European Molecular Biology Laboratory, and the German Cancer Research Center have identified ELP1 as a novel predisposition gene in the SHH subgroup of pediatric medulloblastoma. The work appears as an advance online publication today in Nature.
The intestinal microbiota, composed of the microorganisms that live in our intestines, can give us information about our health, since its composition may depend on factors such as the diet, lifestyle or our pathologies. Moreover, knowing what specific bacteria are in our intestines could help to predict diseases like colon cancer. New advances in genome […]
Using a specialized magnetic resonance imaging (MRI) sensor that can track dopamine levels, MIT neuroscientists have discovered how dopamine released deep within the brain influences distant brain regions.
Houston Methodist nanomedicine researchers are studying a new drug delivery system that transports oral medication via triglycerides that could eliminate the need for injections or IV treatments of some biologic drugs for rheumatoid arthritis and other autoimmune diseases. They're doing this with a diabetes drug that resulted in approximately 25% absorption in mice models, considered […]
Normally, it takes pricey equipment and expertise to create an accurate 3D reconstruction of someone's face. Now, Carnegie Mellon University researchers have pulled off the feat using video recorded on an ordinary smartphone. Shooting a continuous video of the front and sides of the face generates a dense cloud of data. A two-step process developed […]
LAL is an essential biotech resource for sterility testing of medical devices, but harvesting horseshoe crabs from the ocean to produce it puts pressure on vulnerable animal populations. In a new study, researchers have developed an animal-friendly, sustainable aquaculture method that yields an extra-potent LAL that can check for sepsis-causing bacteria and fungi in human […]
thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide
Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,